Cytokine-provided survival signals are known to suppress apoptosis through inhibition of mitochondrial pathways that involve Bcl-2 family members. Here we show that in hematopoietic cells, cytokines also regulate death receptor-mediated pathways. We demonstrate that hematopoietic cytokines such as IL-3 and erythropoietin in normal cells, as well as BCR-ABL oncoprotein in transformed cells, inhibit transcription of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Using small interfering RNAs, we show that the inhibition of TRAIL function is sufficient to partially rescue cytokine-deprived cells from apoptosis. Finally, we demonstrate that cytokine and BCR-ABL suppression of TRAIL transcription is mediated through phosphorylation and inhibition of the forkhead FOXO3a transcription factor. BCR-ABL-induced inhibition of TRAIL transcription in hematopoietic cells may provide a novel mechanism for tumorigenicity in chronic myeloid leukemia.
T he development of hematopoietic cells requires a delicate balance between proliferation and apoptosis that is regulated in part by hematopoietic cytokines (1) . Apoptosis occurs as a default mechanism in cells that fail to receive extracellular survival signals and plays a critical role in controlling the number of cells by eliminating unneeded or damaged cells. In the mammalian system, apoptosis is regulated by two known pathways, the extrinsic death receptor and intrinsic mitochondrial pathways, either alone or through cross talk (1) . Stimulation of either of these pathways results in activation of caspases (2) . The mitochondrial pathway involves a set of proapoptotic (Bid, Bad, Hrk, and Bim) and antiapoptotic (Bcl-2, Bcl-x L , and Mcl-1) members of the Bcl-2 family that together control mitochondrial membrane permeability (1) . The extrinsic apoptotic pathway is activated by stimulation of death receptors, including those for tumor necrosis factor (TNF), CD95͞Fas ligand (FasL) or TNFrelated apoptosis-inducing ligand (Apo-2L͞TRAIL), through binding of their ligands, resulting in activation of a caspase cascade and subsequent cell death (3) . This pathway plays an important role in the immune response involved in the elimination of transformed cells (3) .
Hematopoietic progenitor cells deprived of essential cytokines undergo mitogenic arrest followed by apoptosis (4) . In contrast, oncogenically transformed leukemic cells continuously proliferate and evade apoptosis even in the absence of cytokines (5) . A well characterized example of one such protein causing leukemic transformation is the constitutively active protein tyrosine kinase BCR-ABL (6) . Expression of the chimeric 210-kDa BCR-ABL (P210) in hematopoietic stem cells results in chronic myeloid leukemia, a disease characterized by abnormal cell cycling during the initial chronic phase and resistance to apoptosis during the blast crisis (7, 8) . These features are induced by sustained activation of BCR-ABL protein tyrosine kinase signaling pathways in hematopoietic cells (7, 8) . Many of the same signaling pathways are also activated by cytokines such as IL-3, granulocytic-macrophage colony-stimulating factor (GM-CSF), or erythropoietin (Epo) in hematopoietic cells (9-10).
In cytokine-stimulated or oncogenically transformed cells, such as cells transformed by BCR-ABL, survival signals are generated partly through functional or transcriptional regulation of Bcl-2 family members (11) (12) (13) .
Hematopoietic cytokines have not been found to regulate FasL, a member of the death-inducing TNF family (14) , and it is unclear whether cytokines promote survival by regulation of the extrinsic apoptotic pathway in addition to functional or transcriptional modulation of Bcl-2 proteins. Here, we demonstrate that hematopoietic cytokines in normal cells, and BCR-ABL oncoprotein in transformed cells, promote survival through inhibition of the expression of the TNF family member TRAIL, an activator of the extrinsic apoptotic pathways. We further demonstrate that cytokine or BCR-ABL regulation of the extrinsic apoptotic pathway is mediated, at least partly, through phosphorylation and inhibition of a member of FOXO family of transcription factors.
Real-Time Quantitative RT-PCR. Total RNA was isolated by using the RNeasy Mini Kit (Qiagen, Chatsworth, CA); 3 g for detection of mouse TRAIL or 1 g for mouse Bim and human TRAIL were included in a 50-l reaction containing 25 l of 2ϫ TaqMan universal PCR master mix, 1.25 l of 40ϫ Multscribe Reverse Transcriptase͞RNase inhibitor mix (PE Applied Biosystems), forward and reverse primers (900 nM), fluorogenic TaqMan probe (200 nM), and RNase͞Dnase free water. The thermal cycling conditions of 30 min at 48°C, an initial denaturation step for 10 min at 95°C, and 40 cycles at 95°C for 15 s and 60°C for 1 min were used. Thermal cycling was performed on an ABI Prism 7700 Sequence Detector (PE Applied Biosystems). Primers and Probes are described in Supporting Materials and Methods, which is published as supporting information on the PNAS web site, www.pnas.org.
RNA Interference. Twenty-one nucleotide complementary RNAs with Phos-symmetrical two-nucleotide overhangs to the following regions of mouse TRAIL (bases 278-300 or 328-350) and to 801-823 of Lamin A͞C were obtained from Dharmacon (Lafayette, CO). On average, 200 million BaF3 cells were electroporated with TRAIL or with control siRNA duplexes. Eight million BaF3 cells in 0.8 ml of RPMI were aliquoted per cuvette and electroporated with 160 nM annealed oligonucleotides. Cells were coelectroporated with FITC-conjugated randomly generated annealed oligonucleotides 5Ј-ACUGAACCCGUUUCCACCUTT-3Ј and 5Ј-FITC-AGGUGGAAACGGGUUCAGUTT-3Ј.
Electrophoretic Mobility-Shift Assay. Radiolabeled probes were prepared by filling in a 5Ј overhang in a Klenow reaction in the presence of ␣ 32 P-labeled nucleotides. Oligonucleotides 5Ј-CT-GTCA A A A A A ATA A ATA A ATACATGA A AGAGA-3Ј, WT, or 5Ј-CTGTCTTAATAGTTTAATTATACATGAAA-GAGA-3Ј, mutant TRAIL probe were annealed to 5Ј-TCT-CTTTCA-3Ј; the WT insulin-responsive sequence probe was described (18) . Ten micrograms of nuclear extract and 2ϫ DNA-protein-binding reaction buffer [25 mM Tris, pH 8.0͞200 mM NaCl͞2.5 mM MgCl2͞15% glycerol͞1 mM DDT͞100 g/ml BSA)͞1% Nonidet P-40͞4 g of poly dI-dC͞poly dI-dC (Pharmacia)] were used in reactions, run on a 6% polyacrylamide gel in Tris-glycine buffer (25 mM Tris͞190 mM glycine͞1 mM EDTA) containing 5% glycerol, at 250 V for 120 min. Signals were detected on a Biomax MR (Kodak) film at Ϫ80°C.
Results
Cytokines and BCR-ABL Inhibit Transcription of TRAIL. TRAIL transcription, as measured by quantitative real-time PCR, was up-regulated as a result of withdrawal of IL-3, GM-CSF, or Epo in cytokine-dependent hematopoietic cell lines such as IL-3-dependent pro-B BaF3, GM-CSF-dependent primitive hematopoietic UT7, and Epo-dependent erythroid UT7͞Epo, AS-E2, and HCD57 cells (Table 1) . Cytokine-dependent hematopoietic cell lines that overexpress BCR-ABL can survive and proliferate in the absence of cytokines (ref. 9 and reviewed in ref. 19 ). Overexpression of BCR-ABL oncoprotein significantly suppressed the increase of TRAIL transcription that was observed in response to cytokine deprivation in both human UT7 and murine BaF3 cells. In particular, in IL-3-deprived BaF3 cells, the induction of TRAIL transcript and protein expression, which is suppressed by the expression of BCR-ABL, correlates with cell death (data not shown). Because BCR-ABL and IL-3 activate many of the same signaling pathways in BaF3 cells (reviewed in ref. 19) , this observation suggests a common mechanism for the suppression of TRAIL transcript by BCR-ABL and IL-3. In contrast to TRAIL transcript, transcription of FasL is not detectable (Table 1) . These findings are in agreement with the previous demonstration that FasL is not involved in apoptosis of cytokine-deprived hematopoietic cells (14) .
We, like others (20) , found that Bim, a proapoptotic member of the Bcl-2 family of proteins, was moderately up-regulated in response to IL-3 withdrawal of IL-3-dependent pro-B BaF3 cells (Table 1) and significantly up-regulated in response to Epo withdrawal of Epo-dependent erythroleukemic HCD57 cells (Table 1) . BCR-ABL expression in BaF3 cells reversed the transcriptional up-regulation of Bim observed in response to IL-3 withdrawal (Table 1 ). These findings indicate that, in addition to the intrinsic mitochondrial pathway, the extrinsic death receptor pathway, specifically TRAIL, is also transcriptionally regulated by cytokines and BCR-ABL oncoprotein in both murine and human cells.
Inhibition by siRNA of TRAIL Production in IL-3-Deprived BaF3 Cells
Enhances Survival. Using siRNA (21) to decrease levels of TRAIL that are normally induced in IL-3-starved BaF3 cells, we asked whether induction of TRAIL expression contributes to apoptosis of IL-3-deprived BaF3 cells (Fig. 1 ). BaF3 cells were electroporated either with siRNA duplices targeting TRAIL transcript or control duplices, along with FITC-labeled oligonucleotide duplices. FITC-positive electroporated cells were sorted with fluorescence-activated cell sorting ( Fig. 1 A) and subjected to IL-3 withdrawal for 6 h. As shown in Fig. 1B , the expected 5-fold induction of TRAIL transcript observed in the cells electroporated with control-targeted siRNA was absent in cells with TRAIL-specific targeted siRNA (Fig. 1B) . The annexin Vbinding assay ( Fig. 1D ) showed that after 6 h of IL-3 deprivation, BaF3 cells containing TRAIL-specific siRNAs entered apopto- 
A time course of induction of TRAIL, FasL, and Bim transcripts in response to cytokine deprivation was performed for each cell line, and the value shown corresponds to a particular time point during the starvation. The time points were chosen according to the known time of apoptotic induction and progression on cytokine withdrawal in each cell line. The fold induction in TRAIL transcript on cytokine deprivation is shown as the mean fold induction Ϯ standard deviation. An internal GAPDH control was included throughout the experiments, and the relative ⌬Ct method was used to calculate the fold change in transcript in comparison to control unstarved cells, whose fold change value is set to 1. Results shown are average from at least two independent experiments performed in triplicate. NDT, not detectable transcript; ND, not done.
sis at a significantly lower rate than cells with control siRNAs under the same conditions (Fig. 1D) . In parallel, suppression of TRAIL transcription that is normally induced as a result of IL-3 withdrawal resulted in a slower and delayed apoptotic response of the BaF3 cells (Fig. 1C) . These data implicate TRAIL as one of the factors inducing apoptosis in BaF3 cells in the absence of IL-3. Our data also suggest the existence of additional apoptotic signals, because suppression of TRAIL up-regulation delayed but did not prevent cell death in IL-3-deprived BaF3 cells.
FOXO3a Activates TRAIL Transcription by Binding to TRAIL Promoter
Sequences. Our previous work (15) suggested that the 14-3-3-binding region (22) of the BCR-ABL oncoprotein that is also required for optimum BCR-ABL activation of PI3-kinase͞AKT (23) is essential for BCR-ABL support of survival and maturation of red cell progenitors in the absence of cytokines. 14-3-3 adaptor proteins (24) bind serine͞threonine-phosphorylated targets of AKT and AKT-related kinases including the proapoptotic FOXO3a transcription factor (18) , which, when unphosphorylated and active, enhances transcription of proapoptotic genes such as FasL and Bim (18, 20) . Using the PATSCAN (www-unix.mcs.anl.gov͞compbio͞PatScan͞HTML͞patscan. html) and TFSEARCH (www.cbrc.jp͞research͞db͞TFSEARCH. html) programs, we found that the human TRAIL promoter contains two overlapping FOXO3a consensus-binding sites [(FBST) Ϫ995 to Ϫ986 relative to the translation initiation site] and thus may be a putative target of forkhead FOXO3a transcription factor (Fig. 3A) that by binding to TRAIL promoter mediates activation of TRAIL transcription.
WT (Fig. 2, lane 2) and a constitutively active (data not shown) FOXO3a bound a radiolabeled TRAIL promoter probe (Ϫ1006 to Ϫ974 relative to the translation initiation site) encompassing FBST resulting in a shift in its mobility in a nondenaturing gel.
The formation of the FOXO3a͞TRAIL promoter sequence complex was inhibited by an excess of unlabeled TRAIL oligonucleotide (Fig. 2, lanes 3 and 4) or by an excess of insulinresponsive sequence oligonucleotide (Fig. 2, lane 6 ), known to bind FOXO3a (18) (Fig. 2, lane 5) . Importantly, WT FOXO3a did not bind to a probe containing a mutant FBST (Fig. 2, lane  7) , indicating the interaction between FOXO3a and TRAIL promoter sequence is specific.
To examine the potential of FOXO3a to mediate the activation of TRAIL transcription, reporter constructs with a short sequence (Ϫ1023 to Ϫ973 relative to the translation initiation site of the human TRAIL promoter) containing the two canonical forkhead consensus-binding sites, or mutants in these sites, were used in a reporter gene expression assay (Fig. 3A) . In the absence of serum, WT FOXO3a or the constitutively active FOXO3a (FOXO3a TM) induced high levels of luciferase reporter gene expression (Fig. 3B) . Partial or complete mutation of FBST itself (Fig. 3C, M#1 and  M#2 ), or its flanking residues (Fig. 3C, M#3 ), resulted in 30-40% of maximal luciferase reporter gene expression. Absence of complete abolition of luciferase activity by these mutants (Fig. 3C) suggests that nonconsensus forkhead-binding sequences are located outside of the mutated sequences but within the region Ϫ1023 to Ϫ973 of the human TRAIL promoter. These results are consistent with regulatory functions of residues outside of the core forkhead consensus-binding sites in high-affinity binding of forkhead transcription factors to their targets (25) . Importantly, FBST falls within the region of the human TRAIL promoter with a major function in regulating basal TRAIL activity (26) . In addition, FOXO3a transactivated the full-length Ϸ1.2-kb TRAIL promoter (pGL3-FL-TR) (27) in a reporter gene expression assay (Fig. 3D) . Taken together, these data indicate that FOXO3a activates TRAIL expression by binding to its promoter.
Suppression of TRAIL by IL-3 or BCR-ABL Is Mediated at Least Partly
Through Inhibition of FOXO3a Transcription Factor. To address whether BCR-ABL and cytokines suppress TRAIL expression through inhibition of FOXO3a transcription factor, we first investigated whether cytokine stimulation and͞or BCR-ABL expression results in FOXO3a phosphorylation. As shown in Fig.  4 , FOXO3a was phosphorylated in response to IL-3 stimulation of starved BaF3 cells on T32 and S315 but not on S253. Proportionately more of the same FOXO3a residues were constitutively phosphorylated in BaF3P210 cells even in the absence of IL-3 and͞or serum [Fig. 4 , lanes 6 and 8; note that total FOXO3a protein levels (Fig. 4 Bottom) are lower in BaF3P210 cells, and thus a proportionately higher fraction of FOXO3a is phosphorylated]. Furthermore, IL-3 stimulation of IL-3-starved BaF3P210 cells did not induce any major changes in FOXO3a phosphorylation (Fig. 4, lane 7) . In these experiments, 293T cells overexpressing FOXO3a were included as a positive control (lane 1). The FOXO3a (T32, S253, and S315) residues are phosphorylated with various degrees of specificity by AKT (18) and AKT-related serine threonine kinases of the SGK family in a PI3-kinase dependent manner (28) . Both AKT and SGK kinases are known to phosphorylate T32, but AKT favors S253, and SGK has a marked preference for S315 (28) . Our results suggest that SGK and not AKT may be the preferred kinase in phosphorylating FOXO3a in response to IL-3 stimulation or BCR-ABL expression in BaF3 cells. In agreement with previous reports, we found that FOXO3a was relocalized to the cytoplasm, thus inhibited from activating its target, in response to IL-3 stimulation of starved BaF3 cells and in IL-3-deprived BaF3P210 cells (Fig. 6 , which is published as supporting information on the PNAS web site).
Next, we used an inhibitory mutant of FOXO3a (FOXO3a TM-⌬DB) (29) in BaF3 cells that is a deletion mutant of FOXO3a TM and, like FOXOa3 TM, is constitutively nuclear. FOXO3a TM-⌬DB also lacks the FOXO3a DNA-binding domain and acts in a dominant-negative fashion possibly by binding and depleting FOXO3a transcriptional cofactors (29) . Ectopic expression of the FOXO3a TM-⌬DB (MIG-TM-⌬DB) but not the control vector (MIG) in BaF3 cells resulted in a moderate but significant decrease in TRAIL transcription that is normally induced in response to IL-3 withdrawal (Fig. 5A) , indicating that induction of TRAIL expression in response to IL-3 withdrawal occurs at least partly through activation of FOXO3a. The moderate effect may be due to a limited dominant-negative function of FOXO3a TM-⌬DB. Overexpression of FOXO3a TM induced massive and rapid cell death in BaF3 cells even in the presence of IL-3 (data not shown), and a stable line could not be established. Our observations that (i) TRAIL expression was suppressed in BaF3P210 cells, (ii) FOXO3a was phosphorylated g of the empty vector pECE, pECE-FOXO3a WT, or pECE-FOXO3a TM, and 2 g of WT pGL3-TRAIL. Twenty-four hours after transfection, cells were serum starved in 0.5% FCS for 16 -18 h, harvested, and lysed in 250 l of PLB lysis buffer (Promega). Luciferase (firefly and Renilla) activities were determined by using the dual luciferase assay system. Firefly luciferase activity was normalized to the corresponding Renilla luciferase activity, and results represent mean and SEM of luciferase activity of at least three independent experiments performed in triplicate. (C) Experiments performed as in B; luciferase activity obtained from cotransfection of pECE-FOXO3a WT or pECE empty vector with WT or mutant pGL3-TRAIL reporter constructs in 293T cells is shown. Results represent mean and SEM of luciferase activity of at least three independent experiments. (D) Experiments performed as in B; full-length human TRAIL promoter (-1152 to ϩ1) (27) driving the luciferase gene (pGL-3-FL-TR) was cotransfected with either an empty (pECE) vector or with pECE-FOXO3a WT in 293T cells. An empty pGL3 luciferase vector cotransfected with pECE-FOXO3a WT was used as a control. Results represent mean and SEM of luciferase activity from at least three independent experiments. and inhibited in Baf3P210 cells, and (iii) FOXO3a activates TRAIL transcription through binding to TRAIL promoter suggest that inhibition of FOXO3a in BCR-ABL-transformed cells mediates suppression of TRAIL expression. Ectopic expression of a constitutively active mutant of FOXO3a (FOXO3a TM) but not WT FOXO3a in BaF3P210 cells indeed induced TRAIL transcription (Fig. 5B) . In addition, expression of FOXO3a TM, but not WT FOXO3a, in BaF3P210 cells resulted in a rapid decline of the growth of these cells (Fig. 5C ) and significant induction of apoptosis as detected by the annexin V-binding assay (Fig. 5D ). These results demonstrate that inhibition of forkhead transcription factor in response to hematopoietic cytokines or BCR-ABL oncoprotein blocks TRAIL expression at the level of transcription, and that this results in suppression of apoptosis.
Discussion

TRAIL Induces Apoptosis of Cytokine-Deprived Hematopoietic Cells
and Is Inhibited by BCR-ABL. TRAIL is a type II membrane protein and a member of the TNF family of ligands (30) (31) (32) . TRAIL binds to its cognate death receptors 4 and 5 (DR4 and DR5) in humans and DR5 in mice leading to the activation of caspases and cell death. The physiological role of TRAIL in normal nonimmune hematopoietic development remains unknown (33) . As a promising anticancer agent, recombinant soluble TRAIL induces apoptosis in a broad range of transformed cells, including in BCR-ABL positive chronic myeloid leukemia cells but rarely in nontransformed cells with little or no toxicity (reviewed in refs. 30 and 34-36) . The regulation of TRAIL production is critical for determining the rate of apoptosis vs. survival of hematopoietic cells, because blocking TRAIL synthesis by siRNA significantly delayed apoptosis induced by cytokine deprivation. Understanding the physiological role of TRAIL in hematopoiesis will require further investigation. These findings have broad implications, because they suggest that cytokines, in addition to their direct cellular targets, regulate selectively survival of neighboring cells that express TRAIL receptors. By modulation of the extrinsic death pathway, TRAIL may thus affect the balance of apoptosis and cell division that controls hematopoietic cell production.
Cytokine and BCR-ABL-Mediated Inhibition of TRAIL Transcription Occurs via Phosphorylation and Inhibition of FOXO3a Transcription
Factor. The forkhead family is a large class of eukaryotic winged helix transcription factors playing important roles in embryonic and adult development, including cellular proliferation, differentiation, apoptosis, cell cycle regulation, and DNA repair (37) . In mammals, three members of the FOXO subfamily of the forkhead family have been identified that are homologs of the PI3-kinase͞AKT target DAF-16 in Caenorhabditis elegans (38) . FOXO transcription factors have also been identified at the sites of chromosomal rearrangements in certain human tumors and leukemias (37) . Forkhead transcription factors share a 100-aa sequence, called the forkhead domain (forkhead box or FOX), that mediates their interaction with DNA (37). We found that TRAIL promoter contains two overlapping sequences, highly similar to the forkhead transcription factor consensus-binding sequence (RTAAAY), which bind FOXO3a, resulting in activation of TRAIL transcription (Figs. 2 and 3 ). We further demonstrate that inhibition of TRAIL transcription by cytokine stimulation or BCR-ABL expression is mediated by phosphorylation and inhibition of FOXO3a transcription factor (Figs. 4  and 5) . Thus, by regulating both TRAIL and FasL (18), FOXO3a appears to be a key transcriptional regulator of several components of extrinsic death receptor pathways. However, FOXO3a activation of TRAIL (as demonstrated here) but not FasL (ref.
14 and Table 1 ) results in cell death in cytokine-deprived hematopoietic cells, indicating that FOXO3a induction of the extrinsic death pathways in response to cytokine withdrawal is mediated by TRAIL.
We have demonstrated that hematopoietic cytokines, in addition to modulating several intrinsic apoptotic pathways, suppress at least one extrinsic apoptotic pathway through inhibition of TRAIL synthesis. Equally importantly, we identified FOXO3a transcription factor as a mediator of transcriptional regulation of TRAIL expression downstream of cytokine receptors and the cytoplasmic BCR-ABL protein tyrosine kinase. In addition, our results provide a rationale for the use of TRAIL in the treatment of chronic myeloid leukemia patients (35) . We propose that cytokine regulation of TRAIL expression may be a critical step in the control of hematopoietic cell development.
